Akebia Therapeutics Inc (AKBA) returns
Akebia Therapeutics returns over 10 years
$1,000 invested in Akebia Therapeutics ten years ago was worth $93.21 at the close on October 30, 2026, with dividends reinvested: an average return of -21.1% a year. The same $1,000 in the S&P 500 (SPY) became $4,166.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | -23.2% | — | $767.94 | -0.9% |
| 3 months | -47.7% | — | $523.33 | +2.1% |
| Year to date | -56.1% | — | $438.82 | +11.7% |
| 1 year | -66.4% | — | $336.43 | +12.4% |
| 3 years | -16.5% | -5.8% | $835.30 | +88.5% |
| 5 years | -75.4% | -24.4% | $246.17 | +76.0% |
| 10 years | -90.7% | -21.1% | $93.21 | +316.6% |
Akebia Therapeutics return by calendar year
| Year | AKBA | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | -56.1% | +11.7% | -67.8% |
| 2025 | -15.3% | +17.7% | -33.0% |
| 2024 | +53.2% | +24.9% | +28.3% |
| 2023 | +114.9% | +26.2% | +88.7% |
| 2022 | -74.5% | -18.2% | -56.3% |
| 2021 | -19.3% | +28.7% | -48.0% |
| 2020 | -55.7% | +18.4% | -74.1% |
| 2019 | +14.3% | +31.2% | -16.9% |
| 2018 | -62.8% | -4.6% | -58.3% |
| 2017 | +42.8% | +21.7% | +21.1% |
| 2016 | -19.4% | +12.0% | -31.4% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also: AKBA financials
No forecast, no recommendation. This page describes Akebia Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.